ALX Oncology Holdings Inc
ALXO
ISIN null / Valor 55754366
ALX Oncology Holdings Inc
UMushroom community rating:
About company
ALX Oncology Holdings Inc is a publicly traded, clinical‑stage biotechnology company focused on developing immuno‑oncology therapies that modulate innate and adaptive immune checkpoints to enhance anti‑tumor responses. Its lead program is a CD47‑pathway targeted biologic designed to enable immune‑mediated clearance of cancer cells while minimizing hematologic toxicity, and the company advances this and other candidates in combination with checkpoint inhibitors and tumor‑directed antibodies across solid tumors and hematologic malignancies. ALX’s strategy centers on progressing these programs through clinical trials, pursuing regulatory approval pathways and strategic collaborations to commercialize therapies if clinical results support efficacy and safety.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
265 M
Market cap (USD)
472,946
Daily traded volume (Shares)
1.695 / 1.55
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Matthias Bittel
EQUITIES OF THE SAME SECTOR
